Implantable Bio-Artificial Pancreas (iBAP)

植入式生物人工胰腺 (iBAP)

基本信息

批准号：
9418357
负责人：
SHUVO ROY
金额：
$ 79.25万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-26 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9418357
关键词：
Affect Allogenic American Antibodies Area Arteries Beta Cell Biological Response Modifiers Blood Blood Pressure Blood flow Caliber California Catheters Cell Density Cell Membrane Permeability Cell Survival Cell membrane Cells Characteristics Complement Convection Devices Diabetes Mellitus Diffusion Dose Drops Encapsulated Family suidae Geometry Glucose Healthcare Systems Hour Immune Immunosuppression In Vitro Injection of therapeutic agent Insulin Insulin-Dependent Diabetes Mellitus Islets of Langerhans Transplantation Kidney Kinetics Legal patent Mechanics Membrane Modeling Nutrient Organ Outcome Oxygen Pancreas Pancreas Transplantation Patients Performance Permeability Physiological Polymers Production Quality of life San Francisco Silicon Source Stem cells Supporting Cell Testing Tissue Donors Ultrafiltration Universities Veins base biomaterial compatibility clinical translation clinically relevant common treatment cost cytokine design diabetic fasting glucose glucose monitor glycemic control human embryonic stem cell implantation improved in vivo insulin secretion islet multidisciplinary nanopore pancreas development pre-clinical pressure prevent prototype quantum research clinical testing scaffold solute success

项目摘要

Project Summary Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments can achieve glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. However, previous attempts to develop a bioartificial device have been severely limited by insufficient mass transfer and a limited supply of beta cells. Dr. Shuvo Roy (PI) has developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney project and this project's successes are directly transferrable to the implantable bioartificial pancreas (the iBAP). The ultra-high hydraulic permeability characteristic of the SNM will enable appropriate mass transport (especially oxygen, glucose, and insulin) within to achieve optimal beta cell performance, while the ultra-selective pore characteristic of the SNM enable unprecedented immunoisolation. Also the iBAP will utilize a human embryonic stem cell derived fully functional beta cell that provides and unlimited supply of beta cells for iBAP development and clinical translation.

项目概要大约 300 万美国人和全世界大约 2400 万人受到 1 型糖尿病的影响（T1D）。血糖监测，然后注射胰岛素，同种异体全器官胰腺移植，以及同种异体胰岛移植是 T1D 最常见的治疗方法。这些治疗可以达到许多患者的血糖控制却导致严重的并发症。生物人工胰腺是一种有前途的治疗 T1D，因为它含有功能性胰岛。然而，之前开发生物人工由于传质不足和β细胞供应有限，设备受到严重限制。舒沃博士罗伊（PI）开发硅纳米孔膜（SNM）实现高效血液超滤同时选择性地保留生物人工肾项目的特定溶质，该项目的成功是可直接转移至植入式生物人工胰腺（iBAP）。超高透水性 SNM 的特性将实现适当的质量运输（尤其是氧气、葡萄糖和胰岛素）内实现最佳 β 细胞性能，而 SNM 的超选择性孔特性使前所未有的免疫隔离。 iBAP 还将利用源自功能齐全的人类胚胎干细胞 β 细胞为 iBAP 开发和临床转化提供无限量的 β 细胞。